{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T09:00:12Z","timestamp":1648717212656},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,1,14]],"date-time":"2016-01-14T00:00:00Z","timestamp":1452729600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s11886-015-0689-2","type":"journal-article","created":{"date-parts":[[2016,1,14]],"date-time":"2016-01-14T05:16:38Z","timestamp":1452748598000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current Role of Ivabradine in Stable Coronary Artery Disease Without Heart Failure"],"prefix":"10.1007","volume":"18","author":[{"given":"Mateo","family":"Porres-Aguilar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar C.","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aamer","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,1,14]]},"reference":[{"issue":"4","key":"689_CR1","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1161\/01.RES.63.4.821","volume":"63","author":"JM Canty Jr","year":"1988","unstructured":"Canty Jr JM. Coronary pressure-function and steady-state pressure-flow relations during autoregulation in the un-anesthetized dog. Circ Res. 1988;63(4):821\u201336.","journal-title":"Circ Res"},{"issue":"1","key":"689_CR2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/01.CIR.60.1.164","volume":"60","author":"H Boudoulas","year":"1979","unstructured":"Boudoulas H, Rittgers SE, Lewis RP, et al. Changes in diastolic time with various pharmacologic agents: implication for myocardial perfusion. Circulation. 1979;60(1):164\u20139.","journal-title":"Circulation"},{"issue":"1","key":"689_CR3","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s11936-012-0217-2","volume":"15","author":"K Axsom","year":"2013","unstructured":"Axsom K, Bangalore S. Heart rate in coronary artery disease: should we lower it? Curr Treat Options Cardiovasc Med. 2013;15(1):118\u201328.","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"3","key":"689_CR4","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.amjmed.2014.09.016","volume":"128","author":"M Bohm","year":"2015","unstructured":"Bohm M, Reil JC, Deedwania P, et al. Resting heart rate: risk indicator and emerging risk factor in cardiovascular disease. Am J Med. 2015;128(3):219\u201328.","journal-title":"Am J Med"},{"issue":"4","key":"689_CR5","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S0735-1097(97)00246-5","volume":"30","author":"HJ Levine","year":"1997","unstructured":"Levine HJ. Rest heart rate and life expectancy. J Am Coll Cardiol. 1997;30(4):1104\u20136.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"689_CR6","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/0002-8703(87)90666-1","volume":"113","author":"WB Kannel","year":"1987","unstructured":"Kannel WB, Kannel C, Paffabarger RS, et al. Heart rate and cardiovascular mortality: the Framingham study. Am Heart J. 1987;113(6):1489\u201394.","journal-title":"Am Heart J"},{"issue":"2","key":"689_CR7","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1742-1241.2006.00817.x","volume":"60","author":"S Sulfi","year":"2006","unstructured":"Sulfi S, Timmis AD. Ivabradine: the first selective sinus node If channel inhibitor in the treatment of stable angina. Int J Clin Pract. 2006;60(2):222\u20138.","journal-title":"Int J Clin Pract"},{"issue":"3","key":"689_CR8","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1161\/CIRCRESAHA.109.208041","volume":"106","author":"D DiFrancesco","year":"2010","unstructured":"DiFrancesco D. The role of the funny current in pacemaker activity. Circ Res. 2010;106(3):434\u201346.","journal-title":"Circ Res"},{"issue":"3","key":"689_CR9","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/01.CIR.0000048143.25023.87","volume":"107","author":"JS Borer","year":"2003","unstructured":"Borer JS, Fox K, Jaillon P, et al. Antianginal and anti-ischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, double blind, multicenter, placebo-controlled trial. Circulation. 2003;107(3):817\u201323.","journal-title":"Circulation"},{"issue":"23","key":"689_CR10","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/eurheartj\/ehi586","volume":"26","author":"JC Tardif","year":"2005","unstructured":"Tardif JC, Ford I, Tendera M, et al. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26(23):2529\u201336.","journal-title":"Eur Heart J"},{"issue":"3","key":"689_CR11","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2165\/00003495-200767030-00005","volume":"67","author":"W Ruzyllo","year":"2007","unstructured":"Ruzyllo W, Tendera M, Ford I, et al. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 4-month randomized, double-blind, multicenter, non-inferiority trial. Drugs. 2007;67(3):393\u2013405.","journal-title":"Drugs"},{"issue":"5","key":"689_CR12","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/eurheartj\/ehn571","volume":"30","author":"JC Tardif","year":"2009","unstructured":"Tardif JC, Ponikowski P, Kahan T. Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J. 2009;30(5):540\u20138.","journal-title":"Eur Heart J"},{"issue":"12","key":"689_CR13","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa1406430","volume":"371","author":"K Fox","year":"2014","unstructured":"Fox K, Ford I, Steg PG, et al. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371(12):1091\u20139. This original communication reports the results of the SIGNIFY trial, in which the effects of ivabradine on cardiovascular events in patients with stable coronary artery disease were analyzed.","journal-title":"N Engl J Med"},{"issue":"29","key":"689_CR14","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1093\/eurheartj\/eht101","volume":"34","author":"K Fox","year":"2013","unstructured":"Fox K, Komajda M, Ford I, et al. Effect of ivabradine in patients with left ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trial. Eur Heart J. 2013;34(29):2263\u201370. This pooled analysis demonstrated that ivabradine may be important for the improvement of clinical cardiovascular outcomes in patients with systolic heart failure.","journal-title":"Eur Heart J"},{"issue":"38","key":"689_CR15","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","volume":"34","author":"G Montalescot","year":"2013","unstructured":"Montalescot G, Sechtem U, Achenbach S, et al. European Society of Cardiology (ESC) guidelines on the management of stable coronary artery disease. Eur Heart J. 2013;34(38):2949\u20133003.","journal-title":"Eur Heart J"},{"issue":"22","key":"689_CR16","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.jacc.2012.01.020","volume":"59","author":"K Swedberg","year":"2012","unstructured":"Swedberg K, Komjada M, Bohm M, et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?\u2014findings from the SHIFT study. J Am Coll Cardiol. 2012;59(22):1938\u201345.","journal-title":"J Am Coll Cardiol"},{"issue":"31","key":"689_CR17","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1093\/eurheartj\/ehv150","volume":"36","author":"R Ferrari","year":"2015","unstructured":"Ferrari R, Kim KM. The role of heart rate may differ according to pathophysiological setting: from SHIFT to SIGNIFY. Eur Heart J. 2015;36(31):2042\u20136.","journal-title":"Eur Heart J"},{"issue":"7","key":"689_CR18","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1136\/heartjnl-2014-305482","volume":"100","author":"RI Martin","year":"2014","unstructured":"Martin RI, Pogoryelova O, Koref MS, et al. Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomized controlled trials. Heart. 2014;100(7):1506\u201310.","journal-title":"Heart"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-015-0689-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-015-0689-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-015-0689-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T23:51:49Z","timestamp":1559433109000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-015-0689-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,14]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["689"],"URL":"https:\/\/doi.org\/10.1007\/s11886-015-0689-2","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,14]]},"article-number":"13"}}